The resulting company will operate under the name Opus Genet…
Born from the Foundation Fighting Blindness, the RD (Retinal Degeneration) Fund was created to help accelerate life-changing outcomes for people with retinal degenerations through direct mission related investments in therapeutic companies. The mission of the Foundation Fighting Blindness is to rapidly drive the research that will lead to preventions, treatments and cures for retinal degenerative diseases – including retinitis pigmentosa, age-related macular degeneration, Usher syndrome and the entire spectrum of retinal degenerative diseases. Together, these blinding conditions affect more than 200 million people throughout the world.
IN THE NEWS
10/24/2024
SparingVision Presents Updates on PRODYGY Trial and PHENOROD2 Study…
First oral presentation on PRODYGY at a major cell and gene …
10/22/2024
Ocuphire Pharma Announces Acquisition of Opus Genetics
Acquisition creates a leading, clinical-stage company focuse…
09/23/2024
SparingVision Reports Progress on SPVN06 at Major Ophthalmology Con…
SPVN06 demonstrates continued favorable safety profile at 12…
09/05/2024
Atsena Therapeutics Announces 12-Month Safety and Efficacy Data fro…
Atsena Therapeutics Announces 12-Month Safety and Efficacy D…
08/20/2024
Opus Genetics Receives Rare Pediatric Disease Designation from the…
Priority Review Voucher would be issued upon approval of OPG…
08/14/2024
Atsena Therapeutics Receives Rare Pediatric Disease Designation fr…
Priority Review Voucher would be issued upon approval of ATS…
06/18/2024
Ascidian Therapeutics Enters Collaboration with Roche for Discover…
Ascidian to receive $42 million in initial payment, and up t…
06/13/2024
Opus Genetics Announces $1.7 Million in Project-based Funding from…
$1M TRAP award to support preclinical safety study for gene …
05/13/2024
SparingVision Presents One Year Results from the PHENOROD2 Natural…
• First analysis from PHENOROD2, one of the largest prospec…
05/01/2024
Atsena Therapeutics Announces Positive Clinical Data from the First…
- Subretinal injection of ATSN-201 was well tolerated in all …
04/30/2024
Nacuity Pharmaceuticals Announces First Patients Implanted in Final…
Two patients have been implanted in the final cohort of the …